Download Databook
Download Sample
NA : +1 804 441 9344
sales@towardshealthcare.com
Schedule a Meeting
June 2025
The next-gen delivery market is rapidly advancing on a global scale, with expectations of accumulating hundreds of millions in revenue between 2025 and 2034. Market forecasts suggest robust development fueled by increased investments, innovation, and rising demand across various industries.
The growing incidence of diseases is increasing the use of novel treatment approaches, which in turn, is increasing the demand for next-gen delivery systems. The growing collaborations between the companies are also increasing their development and launches. Moreover, the use of AI is contributing by enhancing its properties, increasing its acceptance rates. This, in turn, is also enhancing the use of various next-gen delivery systems in the biologics and gene therapies. Additionally, their demand in different regions is also increasing, due to growing use of biologics, advancing healthcare, or even due to their rising demand. Thus, all these developments are promoting the next-gen delivery system market growth.
| Metric | Details |
| Market Size | Expected to reach hundreds of millions in revenue by 2034 due to rising demand and innovation. |
| Growth Drivers | AI integration, biologics demand, innovation in nanocarriers, targeted therapies, increasing disease burden. |
| Key Technologies | Liposomal systems, nanocarriers, transdermal patches, hydrogel systems, modular protein adapters, exosomes. |
| AI Role | Enables smart delivery to specific tissues, optimizes drug activity, supports theragnostic development. |
| Recent Collaborations | Sigachi–Respilon (nanofibres); DGIST–Kyungpook Univ (exosome tech); Harbour BioMed–AstraZeneca (multi-specific antibodies). |
| Regional Trends | North America leads (biologics); Asia Pacific fastest-growing (healthcare expansion); Europe growing (R&D, chronic diseases) |
The next generation drug delivery systems provide controlled as well as sustained release of the drugs. At the same time, their use in target-specific action is also growing, which in turn, helps to minimize the side effects. Furthermore, the use of nanocarrier systems and liposomal drug delivery systems is also increasing as they are being used in the delivery of various drugs with poor solubility or instability. Thus, their use in the treatment of cancer, CNS diseases, as well as gene therapies, is increasing.
The use of AI in the next-gen delivery systems is increasing. With the help of AI, smart drug delivery systems are being developed that help to transport drugs to the specific tissues and cells, minimizing the side effects. Moreover, with the use of genetic algorithms, the biological processes and drug activity can be predicted and optimized. Additionally, to merge the novel diagnostic tools with targeted therapies, AI in drug design is being integrated with biotechnology to develop personalized medicine, known as theragnostics.
Increasing Innovations
To improve the safety, efficacy, as well as bioavailability of drugs, various innovations are being developed. At the same time, research and development to formulate a nanocarrier system for site-specific action are also increasing. Similarly, to enhance the stability of various formulations, the use of liposomal or hydrogel delivery systems is also being considered. Furthermore, the use as well as demand for transdermal drug delivery systems with the help of patches is also increasing. Thus, all these innovations are driving the next-gen delivery system market.
Intricate Methods
For the formulation and development of these next-generation delivery systems, the equipment as well as the infrastructure required are sophisticated. At the same time, the procedure or the methods for their development or complex, which requires expertise. Furthermore, the stability issues as well as unwanted interactions can also affect their development, restraining the market growth.
Growing Diseases
There is a rise in the incidence rate of various diseases, such as cancer, autoimmune disease, diabetes, and rare diseases etc. These diseases increase the demand for new treatment approaches, leading to the growth of next-gen delivery system options. Hence, with the help of these next-gen delivery systems, drugs with enhanced stability, bioavailability, efficacy, and targeted action can be delivered. Additionally, they can also show prolonged release patterns, reducing the dosing frequency and increasing patient compliance with the treatment. Thus, this promotes the next-gen delivery system market growth.
The graph represents the total number of autoimmune disorder cases observed in the U.S. It indicates that there will be a rise in cases of autoimmune disorders. Hence, it increases the demand for next-gen delivery systems to enhance the properties of the treatment options for the effective management of these rising disorders. Thus, this in turn will ultimately promote the market growth.
North America dominated the next-gen delivery system market in 2024. The growing use of biologics in the treatment of various diseases in North America is increasing the demand for next-gen delivery systems. This contributes to the market growth. The region is also growing due to the strong presence of key market players. These key players collaborate and contribute to the growing demand for therapeutics and other needs for healthcare needs.
The industries in the U.S. are focusing on the development of various next-gen delivery systems. At the same time, the use of advanced technologies is enhancing the developmental process as well as their safety and efficacy. The U.S. is the largest economy in the North American region with advanced healthcare systems and a highly developed pharma and biotechnology sector.
The industries as well as institutes are developing various next-gen delivery systems for drugs with stability issues. This, in turn, enhances the collaborations between them, which are further supported by the funding provided by the government. The government of Canada is collaborating with other countries for enhancing the healthcare services and products.
Asia Pacific is expected to host the fastest-growing next-gen delivery system market during the forecast period. The healthcare sector in Asia Pacific is expanding due to the growing use of various treatment approaches, as well as research and development. This, in turn, is enhancing the market growth. Asia Pacific has the largest population, which demands a large number of products and services from the healthcare industry. Due to this, the countries in this like China, Japan, India, Thailand, etc, are taking efforts to develop high-end healthcare products.
China consists of a large population, which in turn, increases the risk of diseases. This results in growing adoption of next-gen delivery systems for their effective treatment. Furthermore, they are also developing new minimally invasive next-gen delivery systems. China contributes the largest share because of its innovation and healthcare advancements. After the U.S., China holds second place in the pharmaceutical and biotechnology sectors.
The growing diseases in India are increasing the demand for next-gen delivery systems. Thus, this increases their research and development, which are further supported by the government to make them affordable and easily accessible. India has the largest population, which growing demand for medicine in chronic conditions. As the population grows, the government of India has to take various measures to tackle the demand for products.
Europe is expected to grow significantly in the next-gen delivery system market during the forecast period. Europe is experiencing a rise in the research and development of next-gen delivery systems for the treatment of various chronic diseases. This promotes the market growth.
The healthcare sector in Germany is utilizing next-gen delivery systems for the treatment of cancer or autoimmune diseases. At the same time, new targeted drug delivery systems are also being adopted as well as developed by the industries for diabetes and Alzheimer's disease.
The demand for the use of gene therapies or biologics is increasing in the UK. This, in turn, is increasing the development in the next-gen delivery systems for their targeted release, as well as with new injectable systems. These are furthermore supported by the regulatory bodies.
By Region
June 2025
June 2025
June 2025
June 2025